Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.41 |
| ▸ | RELA | Q04206 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | RHEB | Q15382 | 1/20 | 0.41 |
| ▸ | MGAM | O43451 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | SI | P14410 | 1/20 | 0.40 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.40 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.40 |
| ▸ | BRD4 | O60885 | 1/20 | 0.39 |
| ▸ | PTGER1 | P34995 | 2/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | PPARG | P37231 | 1/20 | 0.38 |
| ▸ | MPO | P05164 | 1/20 | 0.38 |
| ▸ | IDO1 | P14902 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6028879 | 0.84 | PTGER1 (0.53) | PTGER1SLC6A4 | |
| SCHEMBL5274578 | 0.81 | BRD4 (0.44) | L3MBTL1GRM4NPC1NFKB1RAB9A | |
| SCHEMBL28129013 | 0.80 | BRD4 (0.54) | L3MBTL1BRD4PTGER1IDO1 | |
| SCHEMBL28866549 | 0.80 | MAOB (0.49) | L3MBTL1PPARGMPO | |
| SCHEMBL13180647 | 0.77 | GLA (0.41) | L3MBTL1SMN1; SMN2 | |
| SCHEMBL6448897 | 0.76 | MAOB (0.48) | BRD4 | |
| SCHEMBL6452344 | 0.76 | TLR9 (0.51) | NPC1NFKB1RAB9ANFKB2RELA | |
| SCHEMBL3100247 | 0.75 | GRM4 (0.40) | L3MBTL1GRM4NPC1NFKB1RAB9A | |
| SCHEMBL5272223 | 0.75 | L3MBTL1 (0.42) | L3MBTL1GRM4NPC1NFKB1RAB9A | |
| SCHEMBL1577832 | 0.74 | MRGPRX4 (0.46) | NPC1NFKB1RAB9ANFKB2RELA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7803831-B2 | 3-(2-hydroxy-phenyl)-1H-pyrazole-4-carboxylic acid amide derivatives as HSP90 inhibitors for the treatment of cancer | VERNALIS (CAMBRIDGE) LIMITED (GB) | 2010-09-28 | — | — | US | disclosed |
| US-7803831-B2 | 3-(2-hydroxy-phenyl)-1H-pyrazole-4-carboxylic acid amide derivatives as HSP90 inhibitors for the treatment of cancer | VERNALIS (CAMBRIDGE) LIMITED (GB) | 2010-09-28 | — | — | US | disclosed |
| EP-1456180-B1 | 3-(2,4)DIHYDROXYPHENYL-4-PHENYLPYRAZOLES AND THEIR MEDICAL USE | VERNALIS CAMBRIDGE LTD (GB) | 2007-10-03 | — | — | EP | disclosed |
| US-7247734-B2 | 3,4-diarylpyrazoles and their use in the therapy of cancer | VERNALIS (CAMBRIDGE) LIMITED (GB) | 2007-07-24 | — | — | US | disclosed |
| US-7247734-B2 | 3,4-diarylpyrazoles and their use in the therapy of cancer | VERNALIS (CAMBRIDGE) LIMITED (GB) | 2007-07-24 | — | — | US | disclosed |
| US-20070112192-A1 | 3-(2-Hydroxy-phenyl)-1h-pyrazole-4-carboxylic acid amide derivatives as hsp90 inhibitors for the treatment of cancer | VERNALIS (CAMBRIDGE) LIMITED (GB) | 2007-05-17 | — | — | US | disclosed |
| US-20070112192-A1 | 3-(2-Hydroxy-phenyl)-1h-pyrazole-4-carboxylic acid amide derivatives as hsp90 inhibitors for the treatment of cancer | VERNALIS (CAMBRIDGE) LIMITED (GB) | 2007-05-17 | — | — | US | disclosed |
| EP-1567151-B1 | 3-(2-HYDROXY-PHENYL)-1H-PYRAZOLE-4-CARBOXYLIC ACID AMIDE DERIVATIVES AS HSP90 INHIBITORS FOR THE TREATMENT OF CANCER | VERNALIS CAMBRIDGE LTD (GB) | 2006-03-15 | — | — | EP | disclosed |
| US-20050222230-A1 | 3,4-diarylpyrazoles and their use in the therapy of cancer | VERNALIS (CAMBRIDGE) LIMITED (GB) | 2005-10-06 | — | — | US | disclosed |
| EP-1567151-A1 | 3-(2-HYDROXY-PHENYL)-1H-PYRAZOLE-4-CARBOXYLIC ACID AMIDE DERIVATIVES AS HSP90 INHIBITORS FOR THE TREATMENT OF CANCER | Vernalis (Cambridge) Limited (GB) | 2005-08-31 | — | — | EP | disclosed |
| EP-1456180-A1 | 3,4-DIARYLPYRAZOLES AND THEIR USE IN THE THERAPY OF CANCER | Vernalis (Oxford) Ltd (GB) | 2004-09-15 | — | — | EP | disclosed |
| WO-2004050087-A1 | 3-(2-HYDROXY-PHENYL)-1H-PYRAZOLE-4-CARBOXYLIC ACID AMIDE DERIVATIVES AS HSP90 INHIBITORS FOR THE TREATMENT OF CANCER | VERNALIS (CAMBRIDGE) LIMITED (GB) | 2004-06-17 | — | — | WO | disclosed |
| WO-2003055860-A1 | 3,4-DIARYLPYRAZOLES AND THEIR USE IN THE THERAPY OF CANCER | VERNALIS (CAMBRIDGE) LIMITED (GB) | 2003-07-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070112192-A1 | 3-(2-Hydroxy-phenyl)-1h-pyrazole-4-carboxylic acid amide derivatives as hsp90 inhibitors for the treatment of cancer | HSP90AB1, HSP90AA1, HSP90AB2P | L3MBTL1 2768/4885GRM4 4309/4885NPC1 1257/4885 |
| US-20050222230-A1 | 3,4-diarylpyrazoles and their use in the therapy of cancer | HSP90AB1, HSP90AA1, HSP90AB2P | L3MBTL1 1731/4885GRM4 3497/4885NPC1 2190/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.